As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments. Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...
Radiation therapy has been a cornerstone of cancer care since 1896. For more than a century, the central challenge has remained unchanged: How to eradicate tumors while preserving the normal tissues that allow patients not only to survive, but to thrive after treatment.
